<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01139489</url>
  </required_header>
  <id_info>
    <org_study_id>VU University medical center</org_study_id>
    <secondary_id>NTR1861</secondary_id>
    <nct_id>NCT01139489</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Procalcitonin Guided Antibiotic Therapy in Adult Intensive Care Units (ICU's)</brief_title>
  <acronym>SAPS</acronym>
  <official_title>Stop Antibiotics on Procalcitonin Guidance Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Elisabeth-TweeSteden Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diakonessenhuis, Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Isala</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Atrium Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Westfriesgasthuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bronovo Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Center Haaglanden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Slotervaart Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Martini Hospital Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canisius-Wilhelmina Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medisch Spectrum Twente</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Lucas Andreas Ziekenhuis Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial comparing standard-of-care therapy of infections in
      critically ill patients with a procalcitonin-guided approach evaluating efficacy (antibiotics
      consumption) and safety (mortality).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antibiotics are prescribed widely in intensive care units and are linked with high costs and
      the occurence of antimicrobial (multi)resistance. The optimal duration of antibiotic
      treatment is poorly known and often based on consensus guidelines.

      SAPS is a multicenter, prospective, randomized, controlled open-label trial evaluating the
      equivalence/efficacy and safety of procalcitonin-guided treatment of infections in ICU
      patients versus a standard-of-care approach.

      All patients that are admitted to the ICU and for whom systemic antibiotics are prescribed
      for presumed or proven bacterial infections are eligible for this trial. Patients will be
      randomized and stratified according to clinical diagnosis of severe sepsis and septic shock.
      Any patient over the age of 18, admitted to the ICU and receiving antibiotics for an assumed
      infection can be enrolled into this trial. Informed consent has to be obtained in writing
      from the patient of his/her relatives prior to inclusion. In the intervention group daily
      procalcitonin levels be performed and will generate a non-binding stopping advice when
      predefined stopping-rules have been reached. The ultimate decision to stop antibiotics will
      be at the discretion of the physician in both groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Consumption of antibiotics expressed as the Defined Daily Dosage and duration of antibiotic therapy expressed in days of therapy.</measure>
    <time_frame>Between day 1 and D28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>Between D1 and D28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acquisition costs of antibiotics</measure>
    <time_frame>Between D1-D28</time_frame>
    <description>Expressed in euro's</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acquisition costs of procalcitonin</measure>
    <time_frame>Between D1-D28</time_frame>
    <description>Expressed in euro's</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1575</enrollment>
  <condition>Sepsis</condition>
  <condition>Severe Sepsis</condition>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>procalcitonin-guidance</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A daily advise to continue or stop antibiotics based on the measurement of the biomarker procalcitonin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard-of-care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>standard-of-care treatment of ICU infections based upon consensus guidelines and expert opinion</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>procalcitonin-guidance</intervention_name>
    <description>If procalcitonin levels decrease to predefined levels, antibiotic therapy will be discontinued.</description>
    <arm_group_label>procalcitonin-guidance</arm_group_label>
    <other_name>PCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years old

          -  receiving antibiotics for no more than 24 hours for an assumed or proven infection

          -  Informed consent

        Exclusion Criteria:

          -  Failure to obtain written consent to participate

          -  Patients receiving prolonged antibiotic therapies (&gt; 3 weeks, e.g. endocarditis,
             cerebral/hepatic abscess)

          -  Patients with severe infections due to viruses or parasites (e.g. Dengue, Toxoplasma
             gondii, Plasmodium spp.)

          -  Patients infected with Mycobacterium tuberculosis

          -  Patients entering the ICU for post-operative observation and/or on antibiotic
             prophylaxis with an estimated length of stay less then 24 hrs.

          -  Patients suffering from cystic fibrosis

          -  Severely immunocompromised patients such as patients with HIV and with a CD4 count of
             less than 200 cells/mm, neutropenic patients (&lt;500 neutrophils per mL) or patients
             with solid organ transplantation

          -  Moribund patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evelien de Jong, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VU University medical center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.trialregister.nl/trialreg/admin/contactview.asp?CC=1861</url>
    <description>Netherlands Trial Register</description>
  </link>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2010</study_first_submitted>
  <study_first_submitted_qc>June 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2010</study_first_posted>
  <last_update_submitted>January 5, 2016</last_update_submitted>
  <last_update_submitted_qc>January 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>Evelien de Jong</investigator_full_name>
    <investigator_title>drs</investigator_title>
  </responsible_party>
  <keyword>Procalcitonin</keyword>
  <keyword>antibiotic therapy</keyword>
  <keyword>antibiotics</keyword>
  <keyword>sepsis</keyword>
  <keyword>infections</keyword>
  <keyword>biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Calcitonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

